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Abstract
Background: Herpes simplex virus type 2 (HSV-2) infection is the most common cause of genital ulcer disease (GUD)
worldwide. Mother to child transmission causes high morbidity and mortality among infants. Russia is on the brink of a
generalized HIV-epidemic, but Arkhangelsk is still a low-prevalence area. HSV-2 infection is associated with a three-fold
increased risk of HIV-infection. The evidence on the seroprevalence of HSV-2 in Russia is limited. The aim of this study
was to assess HSV-2 seroprevalence and correlates among young adults in the city of Arkhangelsk.
Methods: 1243 adults aged 18-39 years participated in a cross-sectional population-based study, recruited by a public
opinion agency applying a quota sampling method to achieve a data set with similar age- and sex-distribution as the
population in Arkhangelsk. All participants completed a standardized, self-administrated questionnaire and were tested
for HSV-2. Associations between HSV-2 seropositivity and selected sociodemographic and behavioral factors, and self-
reported history of sexually transmitted infections (STIs) were studied by multivariable logistic regression.
Results: HSV-2 seroprevalence was 18.8 %: 12.2 % (95 % confidence interval, CI 9.7-15.2) among men and 24.0 % (95 %
CI 20.1-27.3) among women. Among men, HSV-2 positivity was associated with being divorced/widowed (OR = 2.85,
95 % CI 1.06-7.70), cohabitation (OR = 2.45, 95 % CI 1.07-5.62), and a history of STIs (OR = 2.11, 95 % CI 1.14-3.91). In
women, HSV-2 positivity was associated with high income (OR = 3.11, 95 % CI 1.45-6.71) and having a lifetime number
of sexual partners between 2 and 5 (OR = 2.72, 95 % CI 1.14-6.51), whereas sexual debut at age 18 years or older was
inversely associated with the outcome (OR = 0.47, 95 % CI 0.31-0.72). In both sexes, increasing age was the strongest
correlate of HSV-2 seropositivity in multivariable analyses.
Conclusion: The HSV-2 seroprevalence was twice as high in women than in men and increased with age in both
sexes, and similar to that reported from high-prevalence countries in Europe and the USA. The high prevalence of HSV-
2 among women in childbearing age reveals the potential for HSV-2 transmission from mothers to infants and
increased risk of acquisition HIV-infection; it also contributes to the burden GUD among both sexes. This emphasizes
the public health implications of the HSV-2 epidemic in an urban population in North-West Russia.
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Background
Genital herpes simplex virus type 2 (HSV-2) is one of
the most common sexually transmitted infections (STIs)
worldwide, affecting one in every 10 individuals [1].
HSV-2 goes through periods of non-replication (i.e., la-
tency), and periods of reactivation, during which viral
shedding occurs from the site of initial infection. HSV-2
infection is lifelong, and there is no cure. Most infected
persons are not aware that they carry the virus, but both
asymptomatic and symptomatic persons can transmit
the virus to others. HSV-2 is the dominant cause of
genital ulcer disease worldwide and can cause dissemi-
nated infection and central nervous system disease
complications. Moreover, transmission of HSV-2 from
mother to child during pregnancy causes high morbidity
and mortality among infected infants [1–3]. Most infec-
tions among infants are transmitted during delivery, and
more efficiently transmitted in primary infection near
term than during a long-standing HSV-2 infection [4].
Generally speaking, the more sexual partners people
have in their lifetime, the greater their risk of HSV-2
infection, making HSV-2 seropositivity a marker for
high-risk sexual behavior. Nevertheless, HSV-2 sero-
prevalence is usually higher in women than men in both
high- and low-risk groups [2, 5, 6]. HSV-2 infection is
also an important co-factor for HIV infection [7, 8], as-
sociated with a three-fold increased risk of HIV infection
among both men and women [7].
Routine screening of the general population for HSV-2
is not recommended, and it is impossible to estimate the
prevalence of HSV-2 infection among the general popu-
lation based on clinical case-reporting. Thus, population-
based seroepidemiological studies must be carried out to
determine the burden of HSV-2 infection [5]. The
prevalence of HSV-2 infection varies markedly not
only between, but also within countries and popula-
tion subgroups [6]. Previous studies have shown that
HSV-2 seroprevalence is highest in Africa and South
America, lower in Western and Southern Europe than
in Northern Europe and North America, and lowest in
Asia [5, 6]. However, to our knowledge, only one study
has been published on HSV-2 seroprevalence in the gen-
eral population of Russia in a letter to the editor [9]. An
overall seroprevalence of 20.3 % was reported in a mixed
ethnic population in Siberia, aged 25 to 64 years; 25.3 % in
women and 15.5 % in men.
UNAIDS estimated the HIV-prevalence among the
general population in Russia in the age-group 15-49
years to be about 1.1 %, i.e., on the brink of a generalized
epidemic at the time of the study [10]. Based on case-
reporting, the comparable HIV-prevalence in Arkhangelsk
region was 0,04 % in 2011 among the general population,
rising to 0,08 % in 2015 and on the national level to
0,9 % [11–13]. This underscores that Arkhangelsk region
remains a low-prevalence area for HIV-infection; 63.9 %
of cases were reported as heterosexual and 28.5 % as par-
enteral transmission in the period 1992-2015 [11, 13].
Russia is a multiethnic country with a huge amount of
territory and different levels of economic and social de-
velopment. Northwest Russia has a border with the
European Union, regular international contacts, and dif-
ferent cross-border activities. Travel, culture, socioeco-
nomic factors and mixing of different population groups
contribute to the spread of STIs. Studies on the sero-
prevalence of HSV-2 may help us to understand better
the development of the Russian HIV epidemic, as HSV-2
infection is an important co-factor that contributes to
the spread of HIV in the country. Thus, the aim of this
study was to assess HSV-2 seroprevalence and its corre-
lates among young adults in the city of Arkhangelsk,
Northwest Russia.
Methods
This population-based cross-sectional study was de-
signed as a “second-generation HIV/STI survey”, which
combines biological indicators with data on risk behavior
to provide information for HIV/STI preventive efforts
[14]. First, a pilot study was carried out with 94 partici-
pants. Following the pilot study, the wording of the
questionnaire was improved and a new recruitment pro-
cedure established. The sample size of 1042 was re-
quired to detect odds ratios of two or greater in multiple
logistic regression analysis with up to 7 independent var-
iables for the prevalence of the outcome of 5 % or higher
with 95 % confidence level. We aimed at recruiting 1200
subjects taking into account potential withdrawals and
missing data.
Study population and enrollment
We chose to study young adults because they are sexu-
ally active and at risk for STIs. Census data could not be
used to select a random sample of the population of
Arkhangelsk, as individual-level census data on date of
birth and sex were not available for research purposes.
Instead, participants were recruited by a public opinion
agency applying a quota sampling method to achieve a
data set similar to the population in Arkhangelsk [15].
The agency had a database of all cellphone numbers in
the city, as well as population-based group-level census
data on sex and age distribution (“quotas”) in the eight
districts of Arkhangelsk. In Arkhangelsk region, the
number of cellphones was high in 2011 (1890/1000
population, according to information from Territorial
body of Federal State Statistics Service of the Arkhangelsk
region). Inhabitants were contacted on their cellphones by
the agency, and eligible persons aged 18-39 years were in-
formed about the aims of the study using a script provided
by the study team. The invitees who agreed to participate
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presented themselves at the University Clinic of the
Northern State Medical University. Compared to the
group-level census data from Arkhangelsk, women and
younger individuals were slightly overrepresented in our
study sample (Fig. 1) (Inserted approximately here).
Enrollment went on between September 2010 and
June 2011. Altogether, 4872 respondents completed the
“quotas” according to gender and age-groups. Of them,
3973 agreed to participate. However, the study team ended
inclusion after enrollment of 1265 participants since this
sample size was sufficient according to power calculations.
Upon arrival at the clinic, invitees were again informed
about aims of the study, after which they signed a written
informed consent form. Participants then answered a
standardized, self-administrated questionnaire and had a
blood sample drawn. Participants were paid approximately
14 USD as compensation for travel costs and discomfort
during blood sampling. Twenty-two participants had
missing blood test results and were excluded from the
analyses, resulting in a study sample of 1243 participants.
Description of the variables
The questionnaire collected information on sociodemo-
graphic and socioeconomic factors, sexual and preventive
behavior, alcohol use, a history of STIs/HIV, HIV-testing
and a history of genital herpes. Participants reported their
family income on a scale of 1 to 10, based on how they
thought their income compared to the average income in
Arkhangelsk. We then categorized these responses as low
(1-4), medium (5-7), and high (8-10). Non-smokers
comprised the never-smoking group, and occasional, daily,
and ex-smokers were categorized as ever-smokers. The
variables “ever-use of condoms” and “condom use at
sexual debut” were also dichotomized (Tables 1, 2, 3, 4).
Serological testing
Blood samples were centrifuged and subsequently frozen
at -20 °C at the Research laboratory of the Northern
State Medical University. The laboratory of Arkhangelsk
Clinical Dermatovenerologic Dispensary tested blood
samples for HSV-2 using an enzyme-linked immuno-
sorbent assay (ELISA) for IgG antibodies against the
specific HSV-2 glycoprotein g2, according to the manu-
facturer’s instructions (Vector-Best, Novosibirsk, Russia).
The other Russian population-based study on HSV-2
seroprevalence from Siberia used the same test [9]
Vector-Best is the largest manufacturer of reagent test
kits in Russia, with a well-established quality control sys-
tem. However, we are not aware of any international
publications on the validity of the test kits used in our
study. The instruction manual reports the test to be
100 % sensitive and specific. In real-life, we expect a
lower performance of the test. We will discuss our test
results, based on published guidelines for the manage-
ment and laboratory diagnosis of genital herpes [16, 17].
Statistical analyses
Continuous and categorical variables were analyzed using
unpaired t-tests and Pearson’s chi-squared tests, respectively;
Wilson’s method was applied for the calculation of confi-
dence intervals (CI) for proportions. Logistic regression was
used to assess the association between HSV-2 seropositivity
and potential risk factors, and crude and adjusted odds ra-
tios (ORs) with 95 % CIs are provided. Variables associated
with HSV-2 seropositivity with a p-value <0.05 in crude
analyses were included in the multivariable models; and
analyses were stratified by sex. The Statistical Package for
Social Sciences version 20 (IBM SPSS Inc) was used for all
analyses. The direct standardization technique was applied
to provide the age-standardized HSV-2 seroprevalence to
2010 Arkhangelsk population, based on the 2010 census.
Ethical approval and confidentiality
The Ethical Committee of the Northern State Medical
University in Arkhangelsk approved the study protocol.
(Refer to Declarations). The interview, blood samples,
and blood test results were labeled with a unique per-
sonal code and analyzed in an anonymous manner.
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Fig. 1 Age and sex among participants * and in the general population**, Arkhangelsk, Russia
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Table 1 HSV-2 seroprevalence and correlates among 543 men aged 18-39 years by crude logistic regression analysis in a
population-based study, Arkhangelsk, Russia, 2010-2011
Variables N (%) HSV-2-positive (%) Crude OR (95 % CI)*
Age
18-24 years 204 (37.6 %) 7 (3.4 %) referent
25-29 years 128 (23.6 %) 17 (13.3 %) 4.31 (1.73-10.71)
30-34 years 131 (24.1 %) 26 (19.8 %) 6.97 (2.93-16.59)
35-39 years 80 (14.7 %) 16 (20.0 %) 7.04 (2.77-17.87)
Marrital status
Single 266 (49.0 %) 16 (6.0 %) referent
Divorced/widowed 35 (6.4 %) 10 (28.6 %) 6.25 (2.56-15.23)
Cohabiting 74 (13.6 %) 15 (20.3 %) 3.97 (1.86-8.49)
Married 168 (30.9 %) 25 (14.9 %) 2.73 (1.41-5.29)
Education
Low (secondary school or less) 124 (22.8 %) 23 (18.5 %) referent
Average (secondary/vocational) 147 (27.1 %) 17 (11.6 %) 0.57 (0.29-1.13)
High (incomplete higher/higher) 272 (40.1 %) 26 (9.6 %) 0.46 (0.25-0.85)
Income
Low 92 (16.9 %) 10 (10.9 %) referent
Medium 380 (70.0 %) 46 (12.1 %) 1.13 (0.55-2.33)
High 71 (13.1 %) 10 (14.1 %) 1.34 (0.53-3.43)
Smoking status
Never 151 (27.8 %) 8 (5.3 %) referent
Ever 392 (72.2 %) 56 (14.3 %) 3.10 (1.45-6.67)
Age at sexual debut
<18 years 370 (68.1 %) 53 (14.3 %) referent
≥18 years 173 (31.9 %) 13 (7.5 %) 0.55 (0.39-0.79)
Ever-use of condoms
Yes† 530 (97.6 %) 65 (12.3 %) referent
No 13 (2.4 %) 1 (7.7 %) 0.60 (0.08-4.66)
Condom use at sexual debut
Yes† 262 (48.3 %) 24 (9.2 %) referent
No/don’t remember‡ 281 (51.7 %) 42 (14.9 %) 1.74 (1.02-2.97)
Condom use in a steady relationship
Always/almost always 108 (19.9 %) 8 (7.4 %) referent
Sometimes or rarely 245 (45.1 %) 31 (14.5 %) 1.81 (0.80-4.08)
Never 190 (35.0 %) 24 (16.6 %) 2.07 (0.91-4.74)
Lifetime number of sexual partners
0-1 37 (6.8 %) 3 (8.1 %) Referent
2-5 94 (17.3 %) 5 (5.3 %) 0.64 (0.14-2.81)
≥6 412 (75.9 %) 58 (14.1 %) 1.86 (0.55-6.24)
History of STI
No/don’t know 453 (83.4 %) 44 (9.7 %) Referent
Yes 90 (16.6 %) 22 (24.4 %) 3.01 (1.70 -5.33)
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Results
Of the 1243 participants, 543 were men and 700 were
women (mean age 27.6 years and 27.0 years, respect-
ively). Full-time employment was reported by 64.1 % of
men and 48.1 % of women (data not shown), while
40.1 % of men and 65.8 % of women reported high and
incomplete high education (Table 1 and 2). Seropreva-
lence of HSV-2 and characteristics of the study sample
are presented in Table 1 and 2. The crude overall HSV-2
seroprevalence was 18.8 % (95 % CI 16.8-21.1) and in-
creased with age in women in all age groups and up to
the age of 30 years in men (Fig. 2). (Inserted approxi-
mately here) Seroprevalence was higher in women than
in men in all age groups and twice as high in overall es-
timates (24.0 %, 95 % CI 20.1-27.3 among women and
12.2 %, 95 % CI 9.7-15.2 among men; p < 0.001) in the
sample. After standardization by age, the overall preva-
lence increased to 20.5 % (95 % CI 18.3-22.7) among the
general population; 13.1 % (95 % CI 10.3-15.9) among
men and 26.4 % (95 % CI 23.1-29.7) among women.
In crude analyses for men, HSV-2 seropositivity was
associated with older age, cohabitation, being divorced/
widowed or married, ever-smoking, condom use at sex-
ual debut, a history of STIs, and ever having sex with a
commercial sex worker. High education was associated
with decreased risk of HSV-2 seropositivity compared
with low education (secondary school or less). Men with
age at sexual debut <18 years had an HSV-2 seropreva-
lence that was nearly twice as high as that seen in men
who were older at sexual debut (Table 1).
In crude analyses for women, HSV-2 seropositivity was
associated with older age, cohabitation, being divorced/
widowed or married, ever-smoking, lifetime number of
sexual partners, never-use of condoms, no condom use
at sexual debut, sometimes/rarely using condoms in a
steady relationship, a history of STIs, or binge drinking.
Sexual debut at ≥18 years of age was protective. High
education was associated with a lower risk of HSV-2
seropositivity. Frequency of drinking was not associated
with HSV-2 seropositivity (Table 2).
In adjusted analysis for men, HSV-2 seropositivity was
associated with being ≥30 years of age, being divorced/
widowed or cohabiting, and having a history of STIs
(Table 3). In adjusted analysis for women, HSV-2 sero-
positivity was positively associated with age, high in-
come, and lifetime number of sexual partners; while
sexual debut at ≥18 years of age remained a protective
factor (Table 4). Education and smoking in both sexes,
and age at sexual debut in men were suggestive of an as-
sociation with HSV-2 seropositivity although not reach-
ing the level of statistical significance.
Only 18 participants reported no sexual debut, none
of whom tested positive for HSV-2. Only 3.6 % of re-
spondents reported a history of genital herpes; more
women (4.7 %) than men (2.2 %). In both sexes, one-
third of those who reported a history of genital herpes
had a negative HSV-2 test. HSV-2 positivity was associ-
ated with a history of genital herpes in crude analyses in
men (OR = 16.31, 95 % CI 4.76-54.85) and in women
(OR = 5.40, 95 % CI 2.62-11.10). On the other hand,
86.8 % of all HSV-2-seropositive participants reported
that they had never had genital herpes, i.e. indicating a
very high degree of asymptomatic HSV-2 infection; 3 %
also reported that they did not know, and only 12 % re-
ported a history of genital herpes (data not shown). Pre-
viously HIV testing was reported by 55.4 % of the men
and 73.9 % of the women. No one reported being diag-
nosed with HIV infection. The association between a
Table 1 HSV-2 seroprevalence and correlates among 543 men aged 18-39 years by crude logistic regression analysis in a
population-based study, Arkhangelsk, Russia, 2010-2011 (Continued)
Sex with a commercial sex worker
No 283 (52.1 %) 22 (7.8 %) Referent
Yes/don’t want to answer§ 260 (47.9 %) 44 (16.9 %) 2.41 (1.41-4.16)
Frequency of drinking alcohol
Never, monthly or less 170 (31.3 %) 18 (10.6 %) referent
2-4 times a month 252 (46.4 %) 30 (11.9 %) 1.14 (0.61-2.12)
≥2 times a week 121 (22.3 %) 18 (14.9 %) 1.48 (0.73-2.97)
Binge drinking**
Never 69 (12.7 %) 6 (8.7 %) referent
Ever 474 (87.3) 60 (12.7 %) 1.52 (0.63-3.67)
*Significant association in bold, the statistical significance is at the 0.05 level
†Includes 4 men reporting no sex debut (i.e. without any risk of HSV-2 infection)
‡Includes 24 men who did not remember
§Includes 21 men who did not want to answer
**Drinking 6 or more units in one occasion
Abbreviations: OR odds ratio, CI confidence interval, STI sexually transmitted infection
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Table 2 HSV-2 seroprevalence and correlates among 700 women aged 18-39 years by crude logistic regression analysis in a
population-based study, Arkhangelsk, Russia, 2010-2011
Variables N (%) HSV-2-positive (%) Crude OR (95 % CI)*
Age
18-24 years 293 (41.9 %) 33 (11.3 %) referent
25-29 years 168 (24.0 %) 46 (27.4 %) 2.97 (1.81-4.88)
30-34 years 147 (21.0 %) 51 (34.7 %) 4.19 (2.55-6.88)
35-39 years 92 (13.1 %) 38 (41.3 %) 5.54 (3.20-9.62)
Marrital status
Single 305 (43.6 %) 48 (15.7 %) referent
Divorced/widowed 51 (7.3 %) 18 (35.3 %) 2.92 (1.52-5.60)
Cohabiting 139 (19.9 %) 44 (31.7 %) 2.48 (1.55-3.98)
Married 205 (29.3 %) 58 (28.3 %) 2.11 (1.37-3.26)
Education
Low (secondary school or less) 85 (12.1 %) 30 (35.3 %) referent
Average (secondary/vocational) 155 (22.1 %) 46 (29.7 %) 0.77 (0.44-1.36)
High (incomplete higher/higher) 460 (65.8 %) 92 (20.0 %) 0.46 (0.28-0.76)
Income
Low 115 (16.4 %) 25 (21.7 %) referent
Medium 515 (73.6 %) 119 (23.1 %) 1.08 (0.66-1.76)
High 70 (10 %) 24 (34.3 %) 1.88 (0.97-3.65)
Smoking status
Never 340 (48.6 %) 60 (17.6 %) referent
Ever 360 (51.4 %) 108 (30.0 %) 2.0 (1.40-2.86)
Age at sexual debut
<18 years 356 (50.9 %) 104 (29.2 %) referent
≥18 years 344 (49.1 %) 64 (18.6 %) 0.49 (0.26-0.92)
Ever-use of condoms
Yes† 679 (97.0 %) 159 (23.9 %) referent
No 21 (3.0 %) 9 (42.9 %) 2.45 (1.02-5.93)
Condom use at sexual debut
Yes† 314 (44.9 %) 60 (19.1 %) referent
No/don’t remember‡ 386 (55.1 %) 108 (38.8 %) 1.65 (1.15-2.35)
Condom use in a steady relationship
Always or almost always 162 (23.1 %) 21 (13.0 %) referent
Sometimes or rarely 318 (45.4 %) 78 (24.5 %) 2.18 (1.29-3.69)
Never 220 (31.4 %) 69 (31.4 %) 3.07 (1.79-5.26)
Lifetime number of sexual partners
0-1 97 (13.9 %) 7 (7.2 %) referent
2-5 330 (47.1 %) 74 (22.4 %) 3.72 (1.65-8.37)
≥6 273 (39.0 %) 87 (31.9 %) 6.01 (2.68-13.52)
History of STI
Never/don’t know 543 (77.6 %) 112 (20.6 %) referent
Yes 157 (22.4 %) 56 (35.7 %) 2.13 (1.45-3.14)
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history of HIV-testing and HSV-2 infection was 2.37
(95 % CI 1.34-4.20) among men and 1.77 (95 % CI 1.15-
2.73) among women.
Discussion
To our knowledge, this is the first study on HSV-2 sero-
prevalence in an adult population of Northwest Russia.
Overall, crude HSV-2 seroprevalence in our study of 18-
39-year-olds was 18.8 %: 24.0 % among women and
12.2 % among men. HSV-2 seroprevalence increased
with age, more marked in women than in men. This sex
and age pattern is common in many populations world-
wide, although seroprevalence levels vary greatly [5, 6].
Seroprevalence of HSV-2 in different Russian
subpopulations
We found only one published population-based study in
the Russian general population from Siberia reporting an
overall seroprevalence of 18.6 % among those aged 25-
44 years: 24.1 % in women and 7.5 % and in men [9].
The seroprevalence was lower than observed in our, al-
beit slightly younger, 25-39-year age group (33.2 % in
women and 17.4 % in men). A five-country random-
ized controlled trial on STI/HIV prevention included
18-30-year-old residents of trade school dormitories
in St Petersburg, considered to be at high risk for
STI/HIV [18–20]. An exploratory survey carried out
in St. Petersburg before the trial showed a seroprevalence
of 9.1 % in women and 3.2 % in men [19]. In the baseline
study of the trial one year later, an even lower seropreva-
lence of HSV-2 was found in the much larger study sam-
ple (4.0 % in women and 1.4 % in men) [20]. Our study
carried out approximately a decade later and included the
same age group, revealed a much higher seroprevalence
among young adults in Arkhangelsk (17.1 % in women
and 7.2 % in men, aged 18-29 years).
A pilot study of 50 male commercial sex workers in
Moscow showed a high HIV seroprevalence (16 %),
indicating high-risk behavior, but only 4 % of partici-
pants were HSV-2-seropositive [21]. Moreover, a study
of pregnant women in Israel found that immigrants from
the former Soviet Union had a HSV-2 seroprevalence of
27.5 %, i.e., three-fold higher than Israeli-born women.
This is comparable to the prevalence we found among
women of the same age in Arkhangelsk [22]. Thus our
study is in agreement with previous studies of different
Russian populations groups which reported a much
higher seroprevalence in the general population, than in
high-risk groups [9, 18–22]. This pattern is contrary to
what is usually found, and underscores the heterogeneity
of the HSV-2 seroprevalenc that can be found within
one nation.
Seroprevalence of HSV-2 in other countries
Studies from general population and low-risk popula-
tions from Eastern Europe showed an HSV-2 seropreva-
lence that was either comparable to [23] or lower than
[24–26] what we observed. One study showed great vari-
ations in seroprevalence in Europe, from 24 % in
Bulgaria, 14 % in Germany, 13 % in Finland and 11 % in
Belgium, to 9 % in the Netherlands, 6 % in the Czech
Republic and 4 % in England and Wales [27]. The sero-
prevalence we observed in Arkhangelsk coincides with
higher-prevalence countries in Europe, and is similar to
estimates for Eastern Europe and Central Asia [5]. Our
results are also similar to those reported from the USA,
where overall HSV-2 seroprevalence was 19 % and
women had more than twice the odds of being HSV-2-
seropositive compared to men [28].
Our study lies between the extremes of HSV-2 sero-
prevalence in sub-Saharan Africa, which has the highest
seroprevalence in the world (6 %-57 % among men and
29 %-74 % among women) [29], and Asia, which has a
lower seroprevalence in most general population groups,
i.e. 5 %-7 % among men and 7 %-9 % among women
[30–33]. Looker et al estimated a very high seroprevalence
Table 2 HSV-2 seroprevalence and correlates among 700 women aged 18-39 years by crude logistic regression analysis in a
population-based study, Arkhangelsk, Russia, 2010-2011 (Continued)
Frequency of drinking alcohol
Never, monthly or less 317 (45.3 %) 67 (21.1 %) referent
2-4 times a month 290 (41.4 %) 76 (26.2 %) 1.33 (0.91-1.93)
≥2 times a week 93 (13.3 %) 25 (26.9 %) 1.37 (0.81-2.33)
Binge drinking§
Never 173 (24.7 %) 31 (17.9 %) referent
Ever 527 (75.3 %) 137 (26.0 %) 1.61 (1.04-2.49)
*Significant association in bold, the statistical significance is at the 0.05 level
†Includes 14 women reporting no sex debut (i.e. without any risk of HSV-2 infection)
‡Includes 40 women who did not remember
§Drinking 6 or more units in one occasion
Abbreviations: OR odds ratio, CI confidence interval, STI sexually transmitted infection
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among women in Latin America and the Caribbean
(38,5 %), identical to the reported seroprevalence among
women in Costa Rica, a country in the same region
[5, 34]. However, the seroprevalence among 18-35-
year-old women in this study was 21 % [34], the same
prevalence as in our study women of similar age.
Two population-based studies from South America
showed a lower HSV-2 seroprevalence than what we
observed in Arkhangelsk, and it did not differ be-
tween the sexes [35, 36]. These results reveal the great
differences in HSV-2 seroprevalence in the general popu-
lation worldwide. As in Russia, generalization of HSV-2
prevalence to other population groups should be done
with caution. However, prevalence studies are the first
step in mapping the worldwide spread of this virus.
Factors associated with HSV-2 infection
In our study, age showed the strongest correlation with
HSV-2 seroprevalence in both sexes, which is in agree-
ment with most previous studies and reviews [5, 6, 23–
25, 27, 30, 32, 33, 37].
However, in some studies HSV-2 seroprevalence in-
creased in young adulthood and then stabilized [28], as
it did with men over 30 years in our study; or decreased
at a certain age [9, 35]. Since our oldest participants
were only 39 years old, we cannot rule out the possibility
that prevalence would increase after that age. HSV-2
seroprevalence among women in our study steadily in-
creased with age. In the Siberian study, prevalence in-
creased with age among men, but decreased in the
oldest age group (55-64 years) of women [9]. Thus, com-
paring prevalence in different age-groups within a spe-
cific population, may give an idea of a time trend of the
spread HSV-2 within that particular population.
Nearly two thirds of HIV-transmissions are reported to
be heterosexual in Arkhangelsk region in the period 1992-
2015, and “feminization” of the epidemic is taken place
when HIV-infection presently is spreading to the general
population in Russia [12, 13]. At this stage of the HIV-
epidemic, HSV-2-infected women are of increased risk of
acquisition HIV-infection [7]. Even though Arkhangelsk
region is a low-prevalence are for HIV- infection, we con-
sider the HIV- prevalence to be somewhat higher for the
urban area, Arkhangelsk city, where this study took place.
Prevalence based on case-reporting [11–13] will also in
general be lower than the real prevalence.
In most studies, including ours, women had higher
prevalence of HSV-2 infection than men [5, 6, 19, 20,
23–31, 37], revealing the potential for HSV-2 transmis-
sion from mothers to infants. [4]. Low education has
consistently been associated with HSV-2 seropositivity
[24, 28, 32, 37], and smoking has been reported as a risk
factor for HSV-2 infection in some studies [28, 34], but
not others [24, 37]. For both sexes, we also found such
associations, but it did not reach the level of statistical
significance in the multivariable analyses, although close
for smoking in women. This might be due to insufficient
sample size to detect relatively small effects. Moreover,
some studies have reported an inverse association between
income and HSV-2 seropositivity [37], whereas other have
reported no association [34, 35]. In our study, high income
was the strongest predictors of HSV-2 seropositivity
among women. Further studies, preferably of qualitative
design, needs to clarify this rather unusual finding.
Table 3 HSV-2 infection and correlates among 543 men aged
18-39 years by multivariable logistic regression analysis in a
population-based study, Arkhangelsk, Russia, 2010-2011
Variables Adjusted OR (95 % CI)*
Age
18-24 referent
25-29 2.70 (0.98-7.23)
30-34 3.95 (1.46-10.72)
35-39 4.05 (1.38-11.86)
Marital status
Single referent
Divorced/widowed 2.85 (1.06-7.70)
Cohabiting 2.45 (1.07-5.62)
Married 1.52 (0.73-3.19)
Education
Low (secondary school or less) referent
Average (secondary/vocational) 0.57 (0.28-1.19)
High (Incomplete higher/higher) 0.71 (0.36-1.39)
Smoking status
Never referent
Ever 2.05 (0.89-4.72)
Age at sexual debut
<18 years referent
≥18 years 0.53 (0.26-1.07)
Condom use at sexual debut
Yes† referent
No/don’t remember‡ 1.07 (0.59-1.96)
History of STI
No/don’t know referent
Yes 2.11 (1.14-3.91)
Sex with a commercial sex worker
No referent
Yes/don’t want to answer§ 1.35 (0.73-2.48)
*Significant association in bold
†Includes 4 men reporting no sex debut (i.e. without any risk of
HSV-2 infection)
‡Includes 24 men who did not remember
§Includes 21 men who did not want to answer
Abbreviations: OR odds ratio, CI confidence interval, STI sexually
transmitted infection
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Neither frequency of alcohol drinking nor binge drink-
ing was associated with HSV-2 seropositivity in multi-
variable analyses in our study. This is in agreement with
a study from the USA [28] and in contrast to a study
from Japan [30]. Several [28, 29, 32, 34], but not all [24]
studies have shown an association between HSV-2 sero-
positivity and early age at sexual debut. However, these
studies are not directly comparable, as the definition of
early sexual debut in the studies varied from 13-19 years
of age. We found such an association in crude analyses,
but only persisting in the multivariable analysis for
women. For men, OR was slightly lower in the multivari-
able, compared to the crude analysis (0.53 vs 0.55), sug-
gesting a protective effect of late sexual debut. However,
CI was somewhat wider than in crude analysis, thus not
reaching the significant level. This might be due to lack
of power in the relatively small sample of men with a
lower HSV-2 seroprevalence, compared to women in
our study.
Condom use is reported to have a protective effect
among women in some studies [31, 34], and the same
has been reported for men in Africa [29]. We did see
these associations in crude analyses, but they did not
persist in multivariable analyses. While diverse results
on the protective effect of condom use have been re-
ported, most studies agree that having multiple sexual
partners is a risk factor for HSV-2 seropositivity, espe-
cially among women as found in our study [22, 24, 29,
31, 32, 37]. Such association was not found among men,
who reported far more sexual partners. Different pat-
terns of sexual mixing in women compared to men
might expose women to more risk of HSV-2 infection,
which adds to a greater biological susceptibility to HSV-
2 in women, and may partly explain the higher HSV-2
seroprevalence in women compared to men [33].
The associations between HSV-2 seropositivity and a
history of STIs and herpes were investigated in a
Romanian study, with results that were similar to those
of our study [24]. HSV-1 is increasingly common in
genital sites [2], but we did not test for this virus. Thus,
Table 4 HSV-2 infection and correlates among 700 women
aged 18-39 years by multivariable logistic regression analysis in
a population-based study, Arkhangelsk, Russia, 2010-2011
Variables Adjusted OR for women (95 % CI)*
Age
18-24 referent
25-29 2.84 (1.61-5.03)
30-34 4.36 (2.44-7.79)
35-39 6.47 (3.23-12.97)
Marital status
Single referent
Divorced/widowed 1.11 (0.52-2.38)
Cohabiting 1.40 (0.82-2.39)
Married 1.07 (0.64-1.77)
Education
Low (secondary school or less) referent
Average (secondary/vocational) 0.71 (0.37-1.34)
High (Incomplete higher/higher) 0.62 (0.35-1.10)
Income
Low referent
Medium 1.48 (0.85-2.57)
High 3.11 (1.45-6.71)
Smoking status
Never referent
Ever 1.53 (0.98-2.37)
Age at sexual debut
<18 years referent
≥18 years 0.47 (0.31-0.72)
Ever-use of condoms
Yes† referent
No 2.92 (0.99-8.62)
Condom use at sexual debut
Yes† referent
No/don’t remember‡ 0.94 (0.62-1.43)
Condom use in a steady relationship
Always or almost always referent
Sometimes or rarely 1.30 (0.72-2.33)
Never 1.38 (0.75-2.56)
Lifetime number of sexual partners
0-1 referent
2-5 2.72 (1.14-6.51)
≥6 2.54 (1.03-6.30)
History of STI
No/don’t know referent
Yes 1.45 (0.94-2.24)
Table 4 HSV-2 infection and correlates among 700 women
aged 18-39 years by multivariable logistic regression analysis in
a population-based study, Arkhangelsk, Russia, 2010-2011
(Continued)
Binge drinking§
Never referent
Ever 1.33 (0.80-2.23)
*Significant association in bold
†Includes 14 women reporting no sex debut (i.e. without any risk of
HSV-2 infection)
‡Includes 40 women who did not remember
§Drinking 6 or more units in one occasion
Abbreviations: OR odds ratio, CI confidence interval, STI sexually
transmitted infection
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the HSV-1 virus may, have caused some of the genital
herpes cases reported by HSV-2-negative participants,
and some cases may have been tested in the window
period before seroconversion that may take up to three
months [16]. Finally, our results also demonstrate that
HSV-2 infection is usually asymptomatic, a well-
documented feature of this infection [2, 5], and of the
same magnitude which is estimated in the most recent
global estimates of HSV-2 infections [33].
Limitations and strengths of the study
Due to the cross-sectional design, a temporal relation-
ship between risk behavior and HSV-2 seropositivity
could not be established. As we investigated the young
adult population, we cannot generalize our results to the
whole adult population of Arkhangelsk. In addition, the
study questionnaire contained sensitive questions, which
may have caused social desirability bias due to underre-
porting of high-risk behavior. Blood sampling, seen as
unpleasant by some, may been a deterrent [38]. One of
the potential limitations is the validity of the outcome
measurement since there are no international publica-
tions on the validity of the test kits produced by Vector-
best. The two published European guidelines for the
management and laboratory diagnosis of genital herpes,
agree that the validity of type specific HSV-2 ELISA tests
are high [16, 17]. The East European guidelines refer to
sensitivity and specificity of tests that have been evalu-
ated to be approximately 97 % and 98 %, respectively
[17]. Applied on our study sample, the HSV-2 preva-
lence was slightly reduced to 11.6 % for men, 23.1 % for
women and overall to 17.7 %.
The main strength of our study is its population-based
design, including both sexes. The Arkhangelsk 2010
standardized HSV-2 seroprevalence was slightly higher,
but still within the 95 % CI of the crude seropreva-
lence in our study sample. Considering both age-
standardization and a possible limitation of test validity,
which slightly correct the measured HSV-2 prevalence in
opposite directions, we conclude that the prevalence in
our study probably does not differ much from the real
HSV-2 prevalence in this age-segment of the population
in Arkhangelsk. Even though we could not draw a random
sample from the population, we managed to achieve a
good representation of younger adults in Arkhangelsk
with the sampling method used, which we consider close
to what could have been achieved by conventional prob-
ability sampling. However, our sampling method cannot
rule out selection bias, for instance through recruitment
via cellphone holders, therefore generalization of the study
results should be avoided. Participants received com-
pensation high enough to pay for a taxi to and from
the clinic, and this likely secured participation among
people with low income. To our knowledge, this
study provides the most updated knowledge of HSV-2
seroprevalence and associated factors among the gen-
eral population in Russia.
Conclusion
Associated factors with HSV-2 infection do not differ
much from findings in other studies, The HSV-2 sero-
prevalence was twice as high in women than in men and
increased with age in both genders, and similar to that
reported from high-prevalence countries in Europe and
the USA. The high prevalence of HSV-2 among women
in childbearing age reveals the potential for HSV-2
transmission from mothers to infants and increased risk
of acquisition HIV-infection; it also contributes to the
burden GUD among both sexes. Our findings will be
useful to formulate multifaceted strategies for the pre-
vention and control HSV-2 infection in the general
population in Northwest Russia. More studies HSV-2
seroprevalence are needed among both low- and high-
risk groups in Russia.
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